TITLE

Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans

AUTHOR(S)
Hawkey C J; Jones J I; Atherton C T; Skelly M M; Bebb J R; Fagerholm U; Jonzon B; Karlsson P; Bjarnason I T
PUB. DATE
November 2003
SOURCE
Gut;Nov2003, Vol. 52 Issue 11, p1537
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Cyclooxygenase inhibiting nitric oxide donators (CINODs) are a new class of anti-inflammatory and analgesic drugs that may minimise gastrointestinal toxicity compared with standard non-steroidal anti-inflammatory drugs (NSAIDs) by virtue of nitric oxide donation. METHODS: A proof of concept study of the gastrointestinal safety of AZD3582, the first CINOD available for human testing, was conducted. Thirty one subjects were randomised to receive placebo, naproxen 500 mg twice daily, or its nitroxybutyl derivative AZD3582 in an equimolar dose (750 mg twice daily) for 12 days in a double blind three period crossover volunteer study. At the start and end of each dosing period, gastroduodenal injury was assessed by endoscopy and small bowel permeability by differential urinary excretion of lactulose and L-rhamnose. Pharmacokinetic profiles were assessed at steady state. RESULTS: On naproxen, the mean total number of gastroduodenal erosions was 11.5 (and one subject developed an acute ulcer) versus 4.1 on AZD3582 (p<0.0001). More than half of the subjects had no erosions on AZD3582. Differences were seen for both the stomach and duodenum. Naproxen increased intestinal permeability (lactulose:L-rhamnose ratio 0.030 before v 0.040 after treatment) whereas AZD3582 (0.029 before, 0.029 after; p=0.006 v naproxen) and placebo (0.030 before, 0.028 after; p<0.001 v naproxen) did not. The steady state bioavailability of naproxen metabolised from AZD3582 was 95% (95% confidence interval 87-101%) of that after naproxen administration. CONCLUSIONS: This human study supports animal data showing reduced gastrointestinal toxicity with the CINOD AZD3582. The potential combination of effective pain relief and gastrointestinal protection offered by AZD3582 warrants further evaluation in human clinical studies.
ACCESSION #
11352940

 

Related Articles

  • Nitric Oxide-Releasing Nonsteroidal Anti-inflammatory Drugs Novel Gastrointestinal-Sparing Drugs. Bandarage, Upul K.; Janero, David R. // Mini Reviews in Medicinal Chemistry;May2001, Vol. 1 Issue 1, p57 

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have unacceptable morbidity and mortality due to their gastrointestinal toxicity. Attempts so far to improve the safety profile of NSAIDs have met with limited clinical acceptance. Nitric oxide (NO) functions as an endogenous mediator of gastric...

  • The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Jonzon, Bror; Bjarnason, Ingvar; Hawkey, Chris; Jones, John; Goddard, Andrew; Fagerholm, Urban; Karlsson, P�r // Inflammopharmacology;2003, Vol. 11 Issue 4-6, p437 

    COX-inhibiting nitric oxide donators (CINODs) are a new class of drugs in development for the treatment of acute and chronic pain. They comprise a COX-inhibiting moiety linked to a nitric-oxide-donating component and are designed to provide an innovative mechanism of action of balanced COX...

  • Gastrointestinal Sparing Anti-Inflammatory Drugs - Effects on Ulcerogenic and Healing Responses. Takeuchi, K.; Tanaka, A.; Suzuki, K.; Mizoguchi, H. // Current Pharmaceutical Design;Jan2001, Vol. 7 Issue 1, p49 

    The use of nonsteroidal antiinflammatory drugs (NSAIDs) is associated with a wide array of alterations in gastrointestinal integrity and function. Various approaches have been taken to developing NSAIDs with reduced gastrointestinal toxicity, and few have been successfully reduced the incidence...

  • Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinson's Disease. Asanuma, Masato; Miyazaki, Ikuko // Current Pharmaceutical Design;May2008, Vol. 14 Issue 14, p1428 

    A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown...

  • Cyclo-Oxygenase (COX) Inhibiting Nitric Oxide Donating (CINODs) Drugs: A Review of Their Current Status. Stefano, Fiorucci; Distrutti, Eleonora // Current Topics in Medicinal Chemistry;Feb2007, Vol. 7 Issue 3, p277 

    Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used drugs but their use is hampered by gastrointestinal side effects. Cyclo-oxygenase Inhibitor Nitric Oxide Donors (CINODs) are a new class of antiinflammatory and analgesic drugs generated by adding a nitric oxide generating moiety to...

  • Design of a Heteroaryl Modified, 1,5-Disubstituted Pyrazole Cyclooxygenase-2 (COX-2) Selective Inhibitor. Ezawa, M.; Garvey, D. S.; Janero, D. R.; Khanapure, S. P.; Letts, L. G.; Martino, A.; Ranatunge, R. R.; Schwalb, D. J.; Young, D. V. // Letters in Drug Design & Discovery;Feb2005, Vol. 2 Issue 1, p40 

    Vicinal 1-(4-methylsulfonyl)benzene-5-(3-pyridyl) substituted pyrazole compound containing a nitric oxide (NO)-donating group at the 3-position of the pyrazole ring was synthesized and evaluated for its ability to inhibit COX isozymes in human whole blood. We report here the synthesis of...

  • COX-inhibiting nitric oxide donators (CINODs) � a new paradigm in the treatment of pain and inflammation. Hoogstraate, Janet; Andersson, Lars I.; Berge, Odd-Geir; Jonzon, Bror; �jteg, G�ran // Inflammopharmacology;2003, Vol. 11 Issue 4-6, p423 

    The clinical utility of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief is tempered by their propensity to cause gastrointestinal toxicity. Cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs) are a new class of drugs designed to provide analgesic efficacy...

  • Nitric oxide and the gut injury induced by non-steroidal anti-inflammatory drugs. Whittle, Brendan J. R. // Inflammopharmacology;2003, Vol. 11 Issue 4-6, p415 

    Nitric oxide (NO) can protect the gastrointestinal tract from injury, including that provoked by non-steroidal anti-inflammatory drugs (NSAIDs). This protective profile of NO, which predominantly reflects actions on the microcirculation, is mimicked by NO donors. Moreover, the NO-donating agents...

  • Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Dudhgaonkar, S. P.; Tandan, S. K.; Kumar, D.; Raviprakash, V.; Kataria, M. // Inflammopharmacology;Oct2007, Vol. 15 Issue 5, p188 

    The inflamed mucosa in ulcerative colitis produces high amount of prostaglandin (PG) and nitric oxide (NO) through inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), respectively, implicating them as potential anti-inflammatory drug targets. COX-2 or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics